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The process of angiogenesis involves coordi-
nated endothelial cell (EC) proliferation, in-
vasion, migration, and tube formation. This 
process is induced by vascular growth factors in 
coordination with extracellular matrix–inter-
acting molecules such as integrins (1). Among 
integrins,  αvβ3 heterodimer is known to be 
up-regulated on proliferating endothelial cells 
during angiogenesis and vascular remodeling. 
The disruption of αvβ3 integrin ligation by 
  either blocking antibodies or cyclic peptide an-
tagonists prevented blood vessel formation in 
mouse retina, rabbit cornea, chick chorioallantoic 
membrane, and human skin transplanted onto 
athymic mice (2–6). Histological examination 
of tumor tissue from mice treated with the 
αvβ3 blockers revealed reduction in the tumor 
cell viability and in the vascular density (7). 
These fi   ndings suggested that integrin αvβ3 
provides cellular signals that facilitate EC pro-
liferation and migration during angiogenesis.
However, studies using β3- and β5-null mice 
demonstrated enhanced tumor growth, tumor 
angiogenesis, and vascular endothelial growth 
factor (VEGF)-A–induced vascular permeabil-
ity caused by elevated levels of VEGF recep-
tor (VEGFR)-2 on ECs (8, 9). Therefore, it 
has been concluded that αvβ3 and αvβ5 inte-
grins function as negative regulators of angio-
genesis by restricting the VEGFR-2 expression 
(10). Surprisingly, neither αvβ3 blocking anti-
body nor cyclic peptide antagonists induced 
VEGFR-2 expression in any of the model sys-
tems described in previous studies. This raises 
the possibility that an enhanced expression of 
VEGFR-2 in integrin β3/β5–defi  cient  mice 
could be a result of over-compensation because 
both integrins are pivotal for early embryonic 
vasculogenesis and angiogenesis (11). Another 
hypothesis suggested by authors of previous 
studies is that unligated integrins can act as 
negative regulators of cell survival by initiat-
ing a process referred to as “integrin-    mediated 
cell death.” Therefore, a genetic ablation of a 
proapoptotic stimulus (i.e., unligated αvβ3/
αvβ5) would lead to increased endothelial 
cell survival in vivo, contributing to increased 
blood vessel density (12). Overall, because 
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of the great deal of controversy, the precise role of 
αvβ3   integrin in endothelial cell biology and angiogenesis 
remains unclear.
One of the characteristic features of integrins is the abil-
ity to transduce signals through the cellular membrane in 
both directions. Outside-in signaling informs the cell about 
the extracellular matrix environment. Inside-out signaling, 
known as integrin activation, is the process stimulated by 
agonist (i.e., thrombin or adenosine diphosphate for plate-
lets and growth factor for EC) and results in changes in inte-
grin functional activity (13). The cytoplasmic domains of 
integrins play a vital role in these bidirectional signaling 
  processes. The cytoplasmic domain of the β3 subunit of 
the   vitronectin receptor (αvβ3) undergoes phosphorylation 
in response to cell adhesion to an immobilized ligand (14). 
Phosphorylated β3 can recruit signaling intermediates, Shc 
and GRB2, suggesting that the phosphorylation of the β3 
cytoplasmic domain may induce Ras activation in several 
cell types (15).
To elucidate the role of β3 integrin and its complexes, 
we characterized mice that express a mutant form of β3 in-
tegrin, but not the WT form (knock-in mice). In the mu-
tant, the two tyrosine residues known to be involved in 
integrin signaling, Tyr747 and Tyr759, were substituted to 
phenylalanines. The mutant is unable to undergo phosphor-
ylation of cytoplasmic domain, resulting in defi  cient integ-
rin signaling. In these mice, named DiYF, the mutant β3 
integrin is physically present on all cell types, which should 
prevent any developmental compensatory changes. Recent 
studies using DiYF mice demonstrated that mutation of 
both cytoplasmic tyrosine residues of the β3 cytoplasmic 
domain leads to the defective function of αIIbβ3 on platelets, 
unstable platelet aggregation, and clot retraction in vitro 
and to an enhanced tendency to rebleed in vivo (16, 17). 
Thus, although it is clear that β3 integrin cytoplasmic tyro-
sine motifs play an important role in integrin signaling in 
platelets, its function in endothelial and other specialized 
cells remains unknown.
In the specialized cells, integrins form functional com-
plexes with other receptors on the cell surface. Most often, 
integrins are associated with tyrosine kinase receptors and 
these two types of receptors infl  uence each others activity 
(18, 19). On ECs, αvβ3 integrin is intimately linked with 
the VEGFR-2, because VEGF is able to induce αvβ3 integ-
rin expression and activation (20). At the same time, αvβ3 is 
able to enhance the phosphorylation of VEGFR-2 in re-
sponse to VEGF and subsequent activation of SAPK2/p38 
and FAK.
We sought to directly establish the role of β3 integrin ty-
rosine phosphorylation and integrin signaling in VEGF-stim-
ulated responses of EC and in pathological angiogenesis in 
vivo. To this end, we combined in vivo and ex vivo angio-
genesis assays with an extensive characterization of ECs de-
rived from both WT and DiYF mice to perform a complete 
analysis of the role of integrin β3 and its signaling in func-
tional responses to VEGF.
RESULTS
In ECs, tyrosine phosphorylation of 𝗃3 cytoplasmic domain 
occurs upon adhesion to integrin ligands
Previous studies using cell lines and platelets demonstrated 
that phosphorylation of β3 integrin cytoplasmic tyrosines is 
involved in outside-in integrin signaling. Therefore, we as-
sessed whether EC adhesion to extracellular matrix proteins 
could induce tyrosine phosphorylation of β3 integrin. We 
isolated ECs from the lungs of WT and DiYF mice, plated 
them on various substrates, and assessed the phosphorylation 
of β3 integrin on Tyr747 and Tyr459 (Fig. 1, A and B). Very 
low levels of phosphorylation of WT β3 integrin were 
  observed when cells were kept in suspension or plated on 
poly-l-lysine. Extracellular matrix proteins that serve as li-
gands for αvβ3 such as vitronectin, fi  bronectin, fi  brinogen, 
and gelatin strongly stimulated Tyr759 and Tyr747 phos-
phorylation of WT ECs. Laminin and collagen, which are 
recognized primarily by integrins other than αvβ3, induced 
lower levels of tyrosine phosphorylation. Sodium pervana-
date, known to block phosphatase activity, was used as a pos-
itive control in this experiment. As anticipated, no tyrosine 
phosphorylation of β3 integrin was observed in DiYF EC 
under any conditions.
VEGF treatment of ECs induces tyrosine phosphorylation 
of 𝗃3 integrin
The role of the β3 subunit phosphorylation in extracellular 
matrix recognition was previously assessed in CHO cells 
and K562 cells. These systems do not provide insight into 
the roles of β3 integrin in angiogenesis and in the regulation 
of VEGF or FGF-induced EC responses. These processes 
can be only assessed in ECs expressing appropriate receptors 
and signaling intermediates. We sought to determine 
whether VEGF treatment aff  ected the phosphorylation sta-
tus of β3 integrin. Treatment of ECs with VEGF-A165 
  induced both Tyr747 and Tyr759 phosphorylation in a 
time-dependent manner (Fig. 1 C). Both time curves of β3 
tyrosine phosphorylation followed a bell-shaped pattern, 
which is typical for growth factor–induced responses. Thus, 
not only integrin engagement, but also VEGF treatment 
stimulated tyrosine phosphorylation of β3 subunit in ECs, 
suggesting a possible regulatory role for this process in 
VEGF-induced angiogenesis.
Pathological angiogenesis is impaired in DiYF mice
We next evaluated whether β3 integrin cytoplasmic tyrosine 
motifs are crucial for a complete angiogenic response to 
VEGF in vivo. We implanted VEGF-A–containing Matrigel 
subcutaneously into WT and DiYF mice and assessed the an-
giogenic response based on the amount of hemoglobin ex-
tracted from Matrigel. As shown in Fig. 2 A, the hemoglobin 
concentration was at least fi  vefold lower in Matrigel plugs 
isolated from DiYF mice compared with WT counterparts. 
The vascular density in Matrigel implants was assessed by von 
Willebrand factor (vWF) staining. Only 50% of Matrigel 
plugs from DiYF mice had a distinguishable vasculature and JEM VOL. 203, October 30, 2006  2497
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exhibited staining for vWF (Fig. 2 B, top). The vascular density 
was 4.2-fold lower in DiYF mice than in WT controls 
(P = 0.01) (Fig. 2 B, bottom). Thus, VEGF-induced angio-
genesis was signifi  cantly impaired in DiYF mice.
Further, we assessed tumor-induced pathological angio-
genesis in DiYF and WT mice. To this end, mouse melanoma 
cells (B16F10) were implanted subcutaneously into mice, and 
after 10 d tumors were excised. The average weight of tu-
mors formed in DiYF mice was at least twofold lower than 
average tumor weight in WT mice (0.14 g vs. 0.29 g) (Fig. 
2 C). Tissue section analysis revealed the presence of well-
developed blood vessels that stained positively for CD31, and 
Figure 1.  Extracellular matrix proteins and VEGF induce 𝗃3 in-
tegrin cytoplasmic tyrosine phosphorylation. WT (A) and DiYF (B) cells 
were held in suspension (lane 1); plated on poly L-lysine (lane 2); gelatin, 
with (lane 4) or without (lane 3) pervanadate treatment; or laminin (lane 5), 
collagen (lane 6), vitronectin (lane 7), fi  bronectin (lane 8), or fi  brinogen 
(lane 9) and incubated at 37°C for 60 min. Cell lysates were subjected to 
Western blot analysis using anti–integrin β3 [pY747] antibody (A and B, 
top) or [pY759] antibody (A and B, middle). WT cells plated on vitronectin 
and CHO cell lysates were used as positive and negative control, respec-
tively in panel B (lanes 10 and 11). Cell lysates were also analyzed for β3 
integrin expression as a loading control (A and B, bottom). (C) VEGF in-
duces β3 integrin tyrosine phosphorylation. WT and DiYF mouse lung ECs 
were treated with 20 ng/ml of VEGF-A165 for 0–60 min. Phosphorylation 
statuses of β3Y747 (top) and β3Y759 (middle) were assessed as described in 
Materials and methods. The amount of β3 integrin in all samples was 
quantitated by anti–β3 integrin antibody (bottom). Densitometry analysis 
was performed, and fold changes over control are shown.2498  ROLE OF β3 INTEGRIN IN ANGIOGENESIS | Mahabeleshwar et al.
laminin in tumors from WT mice. In contrast, in tumors 
formed in DiYF mice, blood vessels were sparse and thin 
walled based on laminin staining (Fig. 2 E, top). The vascular 
density in tumors grown in DiYF mice was sixfold lower 
than that in WT mice (P = 0.009) (Fig. 2 E, bottom). Similar 
defects in tumor growth and neovascularization were ob-
served using alternative model of tumor growth in vivo. 
Mouse prostate cancer cells (RM-1) were implanted into 
WT and DiYF mice, and tumor was excised after 10 d. Tu-
mors formed in DiYF mice were smaller than in WT mice 
(1.17 g vs. 0.8 g) (Fig. 2 D). Tissue section analysis indicated 
the presence of substantially larger number of vWF-positive 
blood vessels in tumor developed in WT mice compared 
with DiYF mice (Fig. 2 F). Collectively, our in vivo studies 
demonstrate that tumor angiogenesis is impaired in DiYF 
mice, resulting in reduced tumor growth. Thus, it appears 
that β3 integrin cytoplasmic tyrosine motifs play crucial role 
in the regulation of pathological angiogenesis.
Knowing that monocytes/macrophages use β3 integrin 
for their arrest and extravasation at sites of infl  ammation, we 
assessed whether DiYF mutation aff  ects macrophage recruit-
ment into tumors using anti-F4/80 antibody staining. As 
shown in Fig. 2 G, considerable amounts of macrophages 
were found to be present in tumors implanted in both WT 
and DiYF mice. No substantial reductions in macrophage re-
cruitment were found in DiYF mice. Similar results were 
observed in Matrigel model of VEGF-induced angiogenesis 
(Fig. 2 H). Thus, DiYF mutations within β3 integrin do not 
impair the process of macrophage recruitment in tumors.
Normal embryogenesis and adult vasculature 
development in DiYF mice
Homozygous WT and DiYF mice were bred to obtain ho-
mozygous littermates. The average number of embryos per 
litter was the same. Size and weight of pups were not sub-
stantially diff  erent between WT and DiYF mice. In contrast 
to β3 integrin knockout mice, no embryonic mortality caused 
by placental defects was observed in DiYF mice. DiYF 
mutation did not aff  ected survival of embryos at early stages 
of development. DiYF embryos did not exhibit any broad 
vascular defects (Fig. 3 A). Prenatal DiYF mutant mothers 
Figure 2.  VEGF-induced angiogenesis is impaired in DiYF mice. 
(A) WT and DiYF mice were injected subcutaneously with Matrigel contain-
ing VEGF. Hemoglobin content of Matrigel pellets in WT or DiYF mice was 
measured with the Drabkin reagent. (B) Representative light microscopic 
pictures of Matrigel implant sections stained with vWF antibody from WT 
and DiYF mice. The areas positive for vWF antibody staining, as a percent 
age of total Matrigel cross-sectional area, were measured from eachplug 
section. Bar, 10 μm. (C–F) Functional β3 integrin is essential for enhanced 
pathological angiogenesis. B16F10 mouse melanoma (C) and RM1 mouse 
prostate carcinoma (D) cells were implanted subcutaneously in WT and 
DiYF mice, and tumors were excised after 10 d. Representative melanoma 
(C) and prostate carcinoma (D) tumors formed in WT and DiYF are shown. 
Weights of tumors grown in WT and DiYF mice were measured and repre-
sented in the bar graph. (E) Tumor sections were stained with anti–mouse 
CD31 and antilaminin antibodies. The positively stained blood vessels 
were counted, and results are shown in the bar graph. Bar, 80 μm. 
(F) RM1 tumor sections were stained by anti-vWF antibody. The stained 
blood vessels were counted and represented in the bar graph. Bar, 220 μm. 
(G–H) Macrophage infiltration at the site of angiogenesis in DiYF mice. 
B16F10 tumor (G) and Matrigel (H) sections were stained with macro-
phage marker F4/80. Bars: (G) 80 μm; (H) 40 μm.JEM VOL. 203, October 30, 2006  2499
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Figure 3.  Embryogenesis and vascular phenotypes are broadly 
  normal in adult DiYF mice. (A) Uteri from WT and DiYF females that has 
been bred to WT and DiYF males, respectively. DiYF uteri were completely 
normal and did not show any kind of vascular defects or hemorrhage. 
(B) Homozygous E14 embryos from uterus were normal and did not show 
any differential mortality. (C) 2-d-old typical homozygous WT or DiYF 
pups did not show any differential mortality or vascular defects. (D) Aortas 
from WT and DiYF mice were fi  xed with formalin and embedded in paraffi  n. 
The thickness of aortas was measured and represented in the bar diagram. 
Bar, 180 μm. (E–F) Livers and kidneys from WT and DiYF mice were fi  xed 
and embedded in paraffi  n. Tissue sections were stained by with anti-vWF 
and anti-laminin antibody. Bars: (E, top) 100 μm; (E, bottom) 50 μm; 
(F) 100 μm. (G and H) WT and DiYF skin samples were fi  xed and embedded 
in paraffi  n. Representative tissue sections stained with anti-vWF (G) and 
anti-SMA (H) antibodies are shown. Bars, 100 μm. Positively stained blood 
vessels were counted and represented in bar graphs.2500  ROLE OF β3 INTEGRIN IN ANGIOGENESIS | Mahabeleshwar et al.
Figure 4.  𝗃3 integrin tyrosine 747 and 759 mutations impair ang-
iogenic properties of ECs. (A and B) Functional β3 integrin is essential 
for endothelial cell organization into precapillary cords. WT and DiYF 
mouse lung endothelial cells were seeded on Matrigel-coated plates and 
cells were allowed to adhere. After 24 h, cells were overlaid with Matrigel 
with or without VEGF and maintained in culture. (A) Three random fi  elds 
were photographed periodically using phase–contrast microscope. Bar, 
200 μm. (B) Quantifi  cation of cords numbers per fi  eld (*, P = 0.0004). 
(C and D) β3 integrin cytoplasmic tyrosine residues are critical for capillary 
tube formation. Single cell suspensions of WT and DiYF mouse lung ECs 
were transferred to Matrigel-coated plates and incubated with or without 
VEGF. (C) Endothelial capillary tubes formed in Matrigel were photographed. 
Bar, 200 μm. (D) The length of tubes in random fi  elds from each well 
was analyzed using ImagePro software (*, P < 0.0005). (E) β3 integrin 
cytoplasmic tyrosine motifs are required for normal microvessel growth. 
WT and DiYF mouse aortic rings were embedded in Matrigel and main-
tained at 37°C for 6 d. Microvessel outgrowths from aortic rings were 
observed periodically and photographed. Numbers of microvessel sprouts 
from aortic rings were counted and represented in the bar graph. *, P = 
0.00046. (F) Defective β3 integrin tyrosine phosphorylation reduces VEGF-
induced microvessel outgrowth. WT and DiYF mouse aortic rings were im-
planted in Matrigel with or without VEGF and maintained under aseptic 
condition for 6 d. Microvessel growth from implants was observed peri-
odically and microphotographed. (G) The number of microvessel outgrowth 
from aortic implants was counted and shown in G. *, P < 0.0005. (H) The 
ex vivo aortic ring assay using WT and DiYF aortic rings was performed in JEM VOL. 203, October 30, 2006  2501
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did not suff  er from intrauterine hemorrhage and   placental 
defects (Fig. 3 B) as observed in β3 integrin knockout mice. 
To examine the survival of DiYF mutant mice   after birth, 
the numbers of pups per litter from homozygous crosses were 
monitored. Even after 7 d of postpartum there was no signifi  -
cant diff   erence in mortality of pups between these two 
groups. The DiYF mutant embryos (P = 12) or pups did not 
show any vasculature defects and hemorrhage in skin or in 
gastrointestinal tract as observed in β3 integrin knockout 
mice (Fig. 3 C). Development of large blood vessels exempli-
fi  ed by aorta also appeared to be normal because no signifi  -
cant diff   erences (P = 0.445) in thickness and general 
histological structures of aorta were observed in DiYF mice 
compared with WT counterparts (Fig. 3 D).
To further investigate the eff  ect of DiYF mutation on 
adult vasculature, tissue sections of liver (Fig. 3 E) and kidney 
(Fig. 3 F) were stained for vWF and laminin. No substantial 
diff   erences in blood vessel density of vascular maturation 
were observed in DiYF mice. Vascular density was assessed in 
skin sections from WT and DiYF mice using staining for 
vWF, and there were no signifi  cant diff  erences between these 
two groups (P = 0.725, n = 16; Fig. 3 G). Since vascular 
maturation and pericyte recruitment are known to be essen-
tial for pathological angiogenesis (21), staining for smooth 
muscle actin was performed to reveal mature blood vessels 
(Fig. 3 H). Quantitative results demonstrate the similar den-
sity of smooth muscle actin–positive blood vessels in skins of 
WT and DiYF mice (P = 0.127; n = 11). Since β3 integrin 
is known to be expressed on circulating white blood cells and 
involved in immune response, we demonstrated that the 
numbers of circulating immune cells do not diff  er among 
DiYF and WT mice. The numbers of circulating lympho-
cytes were 86.5 ± 0.93 and 80.1 ± 2.7 × 103 cells/μl for 
WT and DiYF mice, respectively. Monocyte counts were 
also similar: 2.34 ± 0.5 and 2.32 ± 0.6 × 103 cells/μl for 
WT and DiYF mice, respectively. Collectively, these data 
clearly indicate that DiYF mutation did not aff  ect the em-
bryogenesis, organogenesis, postpartum developments, normal 
vascular development and maturation, and levels of circula-
ting white blood cells.
DiYF mutations within the 𝗃3 integrin cytoplasmic domain 
impair angiogenic properties of ECs
Previous studies demonstrated that αvβ3 integrin controls mi-
gration, invasive potential, and angiogenic phenotype of ECs 
(20). Therefore, we assessed whether impaired β3 integrin 
tyrosine phosphorylation aff  ected EC capillary and tube for-
mation ex vivo. WT but not DiYF ECs were able to form 
well-assembled and complete capillary cord-like structures in 
the presence of VEGF-A (Fig. 4 A). In contrast, DiYF ECs 
remained randomly scattered without any signs of organiza-
tion (Fig. 4 A). The number of cords formed by WT EC was 
5.4-fold higher compared with DiYF cells (Fig. 4 B).
A major phenotypic characteristic of ECs is the ability 
to assemble into the interconnected network of tube-like 
structures when grown in a three-dimensional matrix (22). 
WT but not DiYF ECs formed clearly defi  ned and well-
  connected networks of EC tubes (Fig. 4 C). These structures 
were relatively stable and remained well organized for at least 
18 h. As evident from Fig. 4 C, DiYF ECs were not able to 
complete tube formation, and no obvious patterns were 
formed even in the presence of VEGF. The extent of tube 
formation was quantifi  ed by measuring the length of tubes; 
the mean values of three independent experiments are repre-
sented graphically in Fig. 4 D. VEGF treatment induced ap-
proximately threefold increase in the length of the tubes 
formed by WT ECs but had a little eff  ect on DiYF ECs.
𝗃3 integrin cytoplasmic tyrosine motifs controls ex vivo 
angiogenesis in response to VEGF
We next assessed whether DiYF mutations aff  ected an out-
growth of vascular sprouts from aortic segments isolated from 
mice. First, an ex vivo angiogenic assay was performed in 
Matrigel enriched with growth factors. The aortic rings from 
WT mice produced an extensive network of vascular sprouts, 
whereas DiYF aortic rings failed to do so (Fig. 4 E). To elu-
cidate the role of β3 integrin in VEGF-induced responses, the 
aortic ring assay was performed in the presence or absence of 
VEGF using growth factor–reduced Matrigel. Under these 
conditions, aortic rings from WT mice produced a signifi  -
cantly higher number of vascular sprouts both in the absence 
and presence of VEGF than did aortic rings from DiYF mice 
(Fig. 4 F). Quantifi  cation of the number of aortic ring sprouts 
indicated that DiYF cells formed fourfold fewer vascular 
sprouts ex vivo, regardless of stimulation, than did WT aortic 
rings (Fig. 4 G). VEGF produced a small increase in capillary 
formation of DiYF rings; however, the number of sprouts was 
only 20–25% of that observed in WT aortic rings (Fig. 4 G).
To further analyze the capillary growth from aortic rings, 
a detailed kinetic study was undertaken. The time curves of 
vascular growth are presented in Fig. 4 H. In the absence of 
stimulation, very few microvessels were detected in either 
WT or DiYF implants even after a prolonged incubation, 
whereas serum-induced neovascularization was considerably 
higher in WT implants than in DiYF implants (Fig. 4 H). 
The peak values of capillary growth were observed 8 d after 
implantation and were 10 and 45 microvessels per ring for 
DiYF and WT, respectively. VEGF with endothelial growth 
supplement was a stronger stimulus than endothelial growth 
supplement alone, but both produced extensive formation of 
the presence of DMEM without any supplements, with endothelial growth 
supplement, or with VEGF together with endothelial growth supplement. 
Aortic rings were observed every 2 d, numbers of sprouts from each im-
plant were counted, and photographs were taken. Growth kinetics of WT 
and DiYF aortic rings under various conditions were analyzed and the 
growth curves are shown. The data represents the results of three inde-
pendent experiments performed in triplicate.2502  ROLE OF β3 INTEGRIN IN ANGIOGENESIS | Mahabeleshwar et al.
capillaries in WT but not in DiYF aortic rings (Fig. 4 H). 
Collectively, these results indicate that the impaired patho-
logical angiogenesis in DiYF mice was caused by the defec-
tive functional responses of endothelial cells.
𝗃3 integrin cytoplasmic tyrosine motifs regulates 
EC adhesion, spreading, and migration
To further defi  ne the nature of the angiogenic defect ob-
served in DiYF mice, we compared angiogenesis-relevant 
functions of ECs isolated from WT and DiYF mice. We fi  rst 
assessed whether the mutation in β3 integrin cytoplasmic do-
main had any eff  ect on EC adhesion and subsequent cell 
spreading on extracellular matrix substrates. WT and DiYF 
ECs were plated on various integrin ligands and numbers of 
attached and spread cells per fi  eld were counted. WT and 
DiYF ECs adhered and spread equally well on fi  bronectin, 
laminin-1, and collagen-coated plates (Fig. 5, A and B). In 
contrast, a signifi  cant diff  erence (P < 0.001) in the behavior 
of WT and DiYF ECs was found using the αvβ3 ligands vit-
ronectin and entactin. On these substrates, DiYF ECs showed 
a twofold reduction in adhesion and a fourfold decrease in 
the number of spread cells on vitronectin and threefolds on 
entactin (Fig. 5, A and B). To further examine the role of β3 
integrin cytoplasmic tyrosine motifs in regulation of receptor 
ligand-binding strength, we examined cell adhesion under 
conditions of shear stress. WT and excessive DiYF endothe-
lial cells were plated on vitronectin-coated glass coverslips to 
achieve equal number of adherent cells. Then, adherent cells 
were subjected to perfusion with shear rates of 5–30 dyn/cm2 
for 1 min. As shown in Fig. 5 C, shear stress revealed a dra-
matic diff  erence in strength of adhesion between WT and 
DiYF endothelial cells. Shear stress of 10 to 15 dyne/cm2 al-
most completely abolishes DiYF endothelial cell adhesion to 
vitronectin, whereas >60% of WT endothelial cells remained 
tightly adhered to the matrix. Shear rate suffi   cient to wash 
away 50% of adherent cells was 23 and 8 dyne/cm2 for WT 
and DiYF endothelial cells, respectively (Fig. 5 C). This fi  nd-
ing demonstrates that β3 integrin cytoplasmic tyrosine motifs 
regulates ligand-binding strength.
When the migratory activity of WT and DiYF ECs to-
ward various extracellular matrix proteins known to be rec-
ognized by integrins was compared, results were similar to 
those of the adhesion assays: WT and DiYF ECs migrated 
equally well toward fi  bronectin, laminin, and collagen, but 
not toward vitronectin and entactin, where a 2.5-fold re-
duction in migration of DiYF ECs compared with WT was 
observed (Fig. 5 D).
We then compared the VEGF-induced migratory activity 
of WT and DiYF ECs. Stimulation of WT ECs with VEGF 
at 5, 10, and 20 ng/ml induced 1.5-, 2.5-, and 2.9-fold in-
creases of migration compared with untreated ECs (Fig. 5 E). 
DiYF ECs also responded to VEGF stimulation; however, the 
rate of migration was substantially reduced when compared 
with WT cells (Fig. 5 E). Thus, tyrosine phosphorylation of 
αvβ3 integrin appears to play an important role in VEGF-
  induced EC migration to extracellular matrix. To further 
confi  rm these results, we used an alternative and more physi-
ologically relevant method to assess EC migration. WT and 
DiYF ECs were plated on various integrin ligands and were 
allowed to form a confl  uent monolayer. Then, a wound in 
the monolayer was created and the healing process was mon-
itored at diff  erent time points. The quantitative aspects of 
wound recovery and representative images of ECs are pre-
sented in Fig. 5, F and G, respectively. Whereas WT and 
DiYF EC migrated equally well on fi  bronectin, laminin, and 
collagen, a threefold reduction in migration on vitronectin 
was observed in DiYF ECs compared with WT (Fig. 5 F). 
The DiYF mutation impairs αvβ3 integrin-dependent and 
VEGF-stimulated responses of ECs, underscoring the role of 
phosphorylation of tyrosines in the cytoplasmic domain in 
the regulation of a cross-talk between αvβ3 and VEGFRs.
𝗃3 integrin cytoplasmic tyrosine motifs are required 
for sustained activation of VEGFR-2
Next, we sought to identify a molecular mechanism respon-
sible for abnormalities observed in DiYF ECs. Previous stud-
ies using β3-null mice demonstrated that the absence of β3 
leads to up-regulation of VEGFR-2 and consequently to 
augmentation of angiogenic responses of ECs (8). However, 
no diff  erences in VEGFR-2 levels were observed between 
DiYF and WT ECs from lung or aortic origin (unpublished 
data). It was previously shown that integrin β3 forms a com-
plex with VEGFR-2 immediately upon stimulation with 
VEGF, and this association was proposed to be necessary for 
the activation of angiogenic program in ECs (23). Therefore, 
we sought to determine whether the DiYF mutations im-
paired the interaction of β3 integrin with VEGFR-2. Low 
levels of β3–VEGFR-2 interaction were observed in unstim-
ulated WT ECs in suspension or upon adhesion to extracel-
lular matrix. VEGF stimulated a dramatic increase in formation 
of the complex between β3 and VEGFR-2 in WT ECs plated 
on vitronectin, but not in suspension or on laminin, demon-
strating the ligand specifi  city of this phenomenon (Fig. 6 A). 
In contrast, no interaction between β3 and VEGR-2 was 
observed in DiYF ECs under any conditions (Fig. 6 B). Thus, 
β3 tyrosine phosphorylation was essential for an interaction 
between VEGFR-2 and αvβ3 integrin.
 To investigate the mechanism of β3 integrin-dependent 
VEGF signaling, we analyzed the VEGFR-2 phosphoryla-
tion status in WT and DiYF ECs after VEGF stimulation. 
The time courses of VEGR-2 phosphorylation are shown in 
Fig. 6 C. In WT ECs, VEGF induced a bell- shaped response 
with a maximum sixfold increase in VEGFR-2 phosphoryla-
tion relative to unstimulated cells. After 45 min, VEGFR-2 
phosphorylation returned to the control level. In contrast, 
the maximum VEGFR-2 phosphorylation in DiYF ECs 
upon VEGF stimulation was only 2.5-fold over control. Im-
portantly, VEGFR-2 remained phosphorylated three times 
longer in WT ECs than in DiYF ECs (Fig. 6 C). Thus, the 
lack of integrin phosphorylation in DiYF ECs resulted in re-
duced phosphorylation, and therefore activation, of VEGFR-2 
in response to VEGF, which in turn aff  ected all the signaling JEM VOL. 203, October 30, 2006  2503
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Figure 5.  𝗃3 integrin cytoplasmic tyrosine motif is critical for endo-
thelial cell adhesion, spreading, and migration. (A and B) Adhesion and 
spreading of WT and DiYF endothelial cells on various integrin ligands. 
Plates were coated with vitronectin (VN), entactin (EN), fi  bronectin (FN), 
laminin-1 (LM-1), collagen (COL), or BSA. WT and DiYF mouse lung en-
dothelial cell suspensions were plated on each well coated with integrin 
ligands. Numbers of attached and spread cells per fi  eld were counted. Ad-
hesion and spreading of WT ECs on vitronectin was assigned a value of 
100% (*, P = 0.000017 and 0.00003 for cell adhesion and spreading, re-
spectively). (C) β3 integrin cytoplasmic tyrosine motifs regulate ligand bind-
ing strength. WT and 2.25-fold excess DiYF endothelial cells were added on 
vitronectin-coated coverslips to achieve equal number of adherent cells. 
Shear stress of 5–30 dyne/cm2 was applied using a syringe pump for 1 min. 
Numbers of WT endothelial cells adhered to vitronectin under static condi-
tion per fi  eld was assigned the value of 100%, and relative adhesion was 
calculated as described in Materials and methods. (D) Migration of WT and 
DiYF endothelial cells on various integrin ligands. Transwell tissue culture 
inserts were coated with various integrin ligands. WT and DiYF mouse lung 
ECs were seeded into the top chamber. Cells were allowed to migrate, and 
nonmigrated cells adhered to the top surface were removed. The number of 
WT cells that migrated onto the vitronectin-coated insert was assigned a 
value of 100% (*, P = 0.00004). (E) VEGF-induced migration of WT and DiYF 
mouse lung ECs. The migration assay was performed as described in Materi-
als and methods using vitronectin as a substrate. The number of WT ECs 
that migrated in the absence of VEGF was assigned a value of 100%. (F and G) 
Reduced migration of DiYF endothelial cells on β3 integrin ligand. WT and 
DiYF ECs were serum starved and wounded across the cell monolayer by 
scraping away a swath of cells. The wound sites were photographed imme-
diately (time zero) and 12 h later (*, P = 0.00004). The data represent the 
results of three independent experiments. Bar, 220 μm.2504  ROLE OF β3 INTEGRIN IN ANGIOGENESIS | Mahabeleshwar et al.
events downstream of VEGFR-2. To further examine this 
phenomenon WT and DiYF cells were induced with VEGF 
for various time periods and cell lysates were analyzed for 
phosphorylation of extracellular signal–regulated kinase 
(ERK)-1/2 as downstream target molecule of VEGFR-2. In 
WT ECs, VEGF induced strong bell-shaped response with a 
3.5-fold increase in ERK-1/2 phosphorylation relative to 
unstimulated cells within 2.5 to 15 min. In contrast, the max-
imum ERK-1/2 phosphorylation in DiYF ECs upon VEGF 
stimulation was only 2.5-fold over control and appeared only 
after 15 min of VEGF stimulation. Importantly, VEGFR-2–
mediated ERK-1/2 phosphorylation was immediate and lon-
ger in WT ECs than in DiYF ECs (Fig. 6, D and E).
𝗃3 integrin cytoplasmic tyrosine motifs are critical 
for VEGF-induced 𝗂v𝗃3 integrin activation
An intrinsic property of integrin is an increase in soluble li-
gand binding in response to stimulation, a process referred to 
as integrin activation. We and others previously reported that 
VEGF activates αvβ3 integrin on ECs in response to VEGF 
(24). We sought to determine whether impaired activation 
of VEGFR-2 in DiYF ECs resulted in defective αvβ3 activa-
tion by VEGF. VEGF induced a sixfold increase of   fi  brinogen 
binding to WT ECs, but only a threefold   increase in binding 
to DiYF ECs (Fig. 7 A). MnCl2, an agonist known to acti-
vate integrins and stimulate β3 integrin tyrosine phosphory-
lation (25), produced at least a 12-fold increase in fi  brinogen 
binding to WT ECs compared with a 5-fold increase ob-
served in DiYF ECs (Fig. 7 B). The specifi  city of ligand 
binding was confi   rmed by addition of 10-fold excess of 
  unlabeled fi  brinogen. Similar results were observed when in-
tegrin activation was monitored using a monovalent activation-
dependent ligand WOW-1 Fab. VEGF and MnCl2 stimu    lated 
9- and 11-fold increases, respectively, in WOW-1 binding 
to WT ECs and 3.5- and 4-fold increases, respectively, to 
DiYF ECs (Fig. 7 C and Fig. 6 D). Thus, it is   apparent 
that the mutations within the cytoplasmic domain of β3 in-
tegrin in the DiYF mice signifi  cantly impair the process 
of integrin activation, resulting in defective cell adhesion 
and migration.
Figure 6.  𝗃3 integrin cytoplasmic tyrosine residues are required for 
VEGF-induced VEGFR-2 and 𝗃3 integrin interaction. WT (A) and DiYF 
(B) mouse lung endothelial cells were kept in suspension (lanes 1 and 2) or 
plated on vitronectin-coated (lanes 3 and 4) or laminin-coated (lanes 5 and 6) 
plates. These cells were treated with VEGF for 15 min (lanes 2, 4, and 6), 
and cells were lysed, immunoprecipitated with anti–β3 integrin antibody, 
and analyzed by Western blot using anti–VEGR-2 antibody. The same blots 
were reprobed with rabbit anti–mouse β3 integrin antibody to conform 
equal loading (A and B, bottom). (C and E) Mutation of β3 integrin tyrosines 
747 and 759 impairs VEGF-induced VEGFR-2 phosphorylation and down-
stream target molecules. WT and DiYF mouse lung endothelial cells were 
induced with 20 ng/ml VEGF for 0–60 min at 37°C. Cells lysates were im-
munoprecipitated with anti–VEGR-2 antibody and analyzed by Western 
blot using an antiphosphotyrosine antibody. The same blots were reprobed 
with anti–VEGR-2 antibody as loading control. Cell lysates were also ana-
lyzed by Western blot using an anti–p-ERK-1/2 antibody (D, a and c). The 
same blots were reprobed with anti–ERK-1/2 antibody as loading control 
(D, b and d). Densities of the bands were detected, and fold changes over 
control were calculated and represented in the graph (E). The data points 
represent mean ± SD of samples from three separate experiments.JEM VOL. 203, October 30, 2006  2505
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DISCUSSION
To investigate the role played by β3 integrin in pathological 
angiogenesis, we replaced the WT β3 integrin with a mutated 
form unable to undergo phosphorylation, creating the knock-
in mouse DiYF. The mutant β3 integrin is expressed and is 
present on cell surfaces at the normal levels, but is defective 
in signaling. The major advantage of this model is that it 
  allows monitoring of αVβ3 function in primary endothelial 
cells as opposed to model cell lines lacking appropriate recep-
tors and signaling intermediates. The ex vivo and in vitro re-
sults from this model provided novel information that is 
diff  erent from the previously published results from in vitro 
studies and β3 knockout mice experiments (8). A unique 
  aspect of our experimental system is that compensatory or 
over-compensatory responses were not observed; these re-
sponses often occur in knockout models when a protein of 
interest is absent during development (26). Using DiYF 
knock-in mice, we assessed pathological neovascularization 
in vivo and performed an extensive analysis of the underlying 
mechanisms of angiogenesis using ex vivo models. The major 
fi  ndings of this paper are the following. (a) Phosphorylation 
of β3 integrin in WT ECs occurred in response to integrin li-
gation and VEGF stimulation. (b) Lack of β3 integrin phos-
phorylation in DiYF knock-in mice resulted in impaired 
angiogenic response in three distinct in vivo models. As a 
  result of reduced vascularization, tumor growth was signifi  -
cantly inhibited in DiYF mice compared with WT. (c) At the 
same time, DiYF mutation did not aff  ect embryogenesis, or-
ganogenesis, and overall vascular development. In contrast to 
the phenotype of β3 integrin knockout mice, DiYF pups 
were broadly normal and did not show any hemorrhage 
in any organ. Vascular density and maturation in adult DiYF 
animal was also normal, indicating that integrin phosphoryla-
tion is crucial for pathological but not normal vascularization. 
(d) In ECs from DiYF mice, VEGF-induced functional 
  responses (cell adhesion, spreading, migration, and capillary 
tube formation) were defective compared with WT. (e) Lack 
of β3 integrin phosphorylation in DiYF ECs lead to dis-
ruption of the VEGFR-2–β3 integrin complex and lack of 
VEGFR-2 phosphorylation in response to VEGF. (f) VEGF-
induced integrin activation (inside-out signaling) was sup-
pressed in DiYF ECs compared with WT ECs.
Our data show that, in WT ECs, phosphorylation of β3 
integrin occurs in response to integrin ligation and VEGF 
stimulation. The fi  nding that β3 phosphorylation occurs not 
only in response to adhesion to extracellular matrix (i.e., as 
a result of outside-in integrin signaling), but also upon treat-
ment with VEGF, indicates that β3 might play an important 
regulatory role in outside-in integrin signaling, also known as 
integrin activation. In DiYF ECs, β3 cannot be phosphory-
lated, and integrin activation, as measured by soluble ligand 
binding to αVβ3, was considerably reduced compared with 
WT. Previous studies demonstrated that ligation or the treat-
ment with the agonist Mn2+ induces β3 integrin phosphory-
lation in cells other than ECs (25). At the molecular level, it 
was also shown that β3 integrin phosphorylation controls the 
strength of receptor–ligand interaction (27), and might con-
tribute to the overall functional activity of the integrin.
In three distinct models, one that measured capillary for-
mation in Matrigel and two others for vascularity of im-
planted tumors, we observed that pathological angiogenesis 
was severely impaired in DiYF mice. Our fi  ndings are consis-
tent with the results of studies using αVβ3 blocking antibodies 
and demonstrate a key role for αVβ3 integrin in angiogenesis, 
suggesting that β3 integrin is a positive regulator of angiogen-
esis and its phosphorylation is a critical step in EC responses 
during VEGF-induced neovascularization. Further, our fi  nd-
ings provide an additional argument that increased angiogen-
esis observed in β3 knockout mice (8) is a result of molecular 
compensation via VEGR-2; this emphasizes the physiological 
importance of VEGR-2–αVβ3 cross-regulation in ECs, but 
does not refl  ect the true function of αVβ3 integrin in angio-
genesis in an organism expressing normal amounts of this re-
ceptor. Since our experimental approach does not involve a 
complete deletion of β3 integrin from the cell surface, it does 
not trigger compensatory   responses (i.e., up-regulation of 
Figure 7.  𝗃3 integrin phosphorylation controls integrin activation. 
DiYF ECs exhibited reduced fi  brinogen binding in response to growth factors. 
WT and DiYF mouse lung ECs were serum starved for 4 h and washed 
twice with PBS. These cells were incubated with FITC fibrinogen in the 
presence or absence of 20 ng/ml VEGF for 45 min at 37°C. Cells were 
fi  xed, washed, and analyzed by fl  ow cytometry. Bars represent mean fl  uo-
rescence intensity of three independent experiments performed in tripli-
cates (A). WT and DiYF mouse lung endothelial cells were stimulated 
with 1 mM MnCl2. MnCl2-induced fi  brinogen binding was diminished by 
10-fold excess of unlabeled fi  brinogen showing specifi  city of binding (B). 
(C and D) β3 integrin cytoplasmic tyrosine motif is essential for interaction 
with monovalent ligand WOW-1 Fab. WT and DiYF mouse lung endothelial 
cells were serum starved for 4 h, washed twice with PBS, and incubated 
with WOW-1 Fab in the presence or absence of 20 ng/ml VEGF for 45 min 
at 37°C. Cells were washed and incubated with FITC-conjugated goat 
anti–mouse IgG for 30 min at room temperature. Cells were fi  xed with 
0.4% formaldehyde, washed, and analyzed by fl  ow cytometry. Bars repre-
sent mean fl  uorescence intensity of three independent experiments per-
formed in triplicates (C). WT and DiYF mouse lung endothelial cells were 
also induced with 1 mM MnCl2 as positive control (D). Asterisks indicates 
signifi  cant difference between WT and DiYF endothelial cells (P < 0.05). 2506  ROLE OF β3 INTEGRIN IN ANGIOGENESIS | Mahabeleshwar et al.
VEGR-2). The phenomenon of molecular compensation—
in many cases, over-  compensation—in knockout mice has 
been described in numerous reports and represents a major 
drawback of the knockout approach. Frequently, the loss of 
a particular protein results in increased expression of other 
members of the same family, revealing the functional redun-
dancy (28). It has been shown, for example, that αVβ5 integrin 
can compensate for the loss of α5β1 integrin (26). Analysis of 
the substitute molecule, which is structurally and functionally 
distinct from the targeted protein (29, 30), might reveal new 
connections within the molecular network. It is intriguing 
that VEGR-2, a tyrosine kinase receptor, can compensate for 
the loss of a member of integrin family of cell adhesion mol-
ecules, as VEGR-2 is distinct in regard to ligand repertoire 
and other functional aspects.
In the present study, impaired angiogenesis in DiYF 
knock-in mice resulted from the decreased adhesion, spread-
ing, and migration of ECs in response to VEGF. Interestingly, 
impaired cell adhesion and migration was observed only on 
vitronectin as a substrate, but not on fi  bronectin or collagen. 
Nevertheless, ex vivo angiogenesis in Matrigel, and in vivo 
angiogenesis, was defective, emphasizing a role for αVβ3 in 
this process. At the molecular level, this study demonstrated 
that impaired tyrosine phosphorylation of β3 integrin in DiYF 
ECs abrogated αVβ3–VEGFR-2 complex formation and re-
sulted in dramatically reduced phosphorylation of VEGFR-2 
upon VEGF stimulation. Since VEGF (via VEGFR-2 as its 
major functional receptor on ECs) induces phosphorylation 
of αVβ3 and phosphorylation of αVβ3, in turn, is required for 
complete and sustained phosphorylation of VEGFR-2, it 
can be concluded that these two receptors are able to cross-
activate each other in ECs, therefore forming a functional 
partnership that is essential for successful angiogenesis.
Collectively, our fi  ndings demonstrate that αVβ3 and its 
inside-out and outside-in signaling is essential for pathologi-
cal angiogenesis and undoubtedly represents a promising 
  target for pharmaceutical approaches. However, when devel-
oping new inhibitors for angiogenesis, one should take into 
consideration the complexity of αVβ3 regulation, its interac-
tions with other receptors, and possible compensatory changes 
resulting from its suppression.
MATERIALS AND METHODS
Animals. DiYF mice were generated in the laboratory of Dr. David 
R. Phillips and maintained on a C57/Bl6 background (seven generations of 
backcrossing). 6–8-wk-old WT and DiYF mice were used in our study. We 
performed all procedures according to protocols approved by Cleveland 
Clinic Foundation Institutional Animal Care and Use Committee.
In vivo Matrigel plug assay. WT and DiYF animals received an abdomi-
nal subcutaneous injection of 500 μl Matrigel mixed with VEGF (60 ng/ml) 
and heparin (60 units/ml). After 7 d, the animals were killed and dissected. 
Matrigel plugs were removed and digested using 5 ml Drabkin reagent, and 
quantifi  cation of neovascularization was assessed using a hemoglobin assay as 
per the manufacturer’s protocol.
Tumor angiogenesis. WT and DiYF mice were subcutaneously injected 
with freshly harvested 106 B16F10 mouse melanoma or RM-1 mouse 
  prostate cancer cells. Tumors were collected 10 d after injection and tumor 
weights were measured. Tumors were also photographed and processed for 
immunohistochemical staining.
Immunohistochemistry and image analysis. Immunohistochemistry 
and image analysis was performed as described previously (21). Matrigel 
plugs or tumor tissues sections were stained with polyclonal rabbit anti-vWF 
antibody (Abcam, Inc.) or rat anti-F4/80 (Serotec, Inc). Sections were 
counterstained with hematoxylin. WT and DiYF skin, liver, and kidney tis-
sue samples were processed and stained for vWF or laminin. B16F10 tumor 
sections were stained with polyclonal anti-CD31 (Fitzgerald Industries Intl.) 
and anti-laminin (Sigma-Aldrich) antibody.
Aortic ring assay and isolation of endothelial cells. The mouse aortic 
ring assay was performed as described previously (21). WT and DiYF mouse 
lungs were excised, minced, and digested using collagenase-dispase reagent 
(3 mg/ml). Digests were strained and the resulting cell suspension was plated 
on fl  asks coated with 1 mg/ml fi  bronectin. Endothelial cells were isolated 
and characterized as described previously (31).
Cell adhesion and cell spreading assay. The cell adhesion assay was per-
formed as described previously (32). Mouse lung endothelial cell suspensions 
were added to ligand-coated wells and placed in humidifi  ed incubator for 
45 min. The wells were gently washed three times with DMEM and photographs 
were taken. The numbers of attached and spread cells per fi  eld were counted. 
  Adhesion assay under shear stress conditions was performed as described previ-
ously using fl  ow chamber (33). Prior to the beginning of the experiment WT 
and 2.25-fold excess DiYF endothelial cells were added on vitronectin-coated 
coverslips to achieve approximately equal number of adherent cell population 
and allowed to interact with the matrix for 15 min. These coverslips were gen-
tly washed and introduced into the bottom of the fl  ow chamber. Shear stress 
of 5–30 dyne/cm2 was applied using syringe pump for 1 min. Number of 
WT endothelial cells adhered to vitronectin under static condition per fi  eld 
was   assigned the value of 100% and relative adhesion was calculated.
Endothelial cell migration and wound healing assay. Endothelial cell 
migration assay was performed as described previously (24). WT and DiYF 
mouse lung endothelial cells were grown to confl  uence in 12-well plates 
precoated with various integrin ligands. Cells were serum starved and then 
a wound was created. Images were recorded immediately after wounding 
(time zero) and 12 h later. Cell migration was quantifi  ed using image analysis 
of fi  ve randomly selected fi  elds of denuded area. The mean wound area is 
expressed as percent of recovery (% R) from three identically treated plates 
using the equation % R = [1− (Tt/T0)] × 100, where T0 is the wounded 
area at 0 h and Tt is the wounded area after 12 h.
WOW-1 and fi  brinogen binding assay. WOW-1 Fab binding assay was 
performed as described previously (34). To assess fi  brinogen binding, WT 
and DiYF mouse lung endothelial cells were serum starved for 4 h and fur-
ther induced with 20 ng/ml VEGF-165 or 1 mm MnCl2. FITC-labeled 
  fi  brinogen was added at a fi  nal concentration of 200 nM for 45 min. Cells 
were fi  xed and washed twice with ice-cold PBS. FACS was performed using 
a FACS Calibur (Becton Dickinson), and data were analyzed using Cell-
Quest software program.
Endothelial tube and precapillary cord formation assay. The forma-
tion of vascular tube-like structures by WT and DiYF mouse lung endothe-
lial cells were assessed on the basement membrane matrix preparation. WT 
and DiYF mouse lung endothelial cells were seeded on Matrigel-coated 
plates. Medium with or without 20 ng/ml VEGF was added, and cells were 
further incubated at 37°C for 8 h. The tube formation was observed using an 
inverted phase–contrast microscope, and photographs were taken from each 
well. Using ImagePro software, the degree of tube formation was quantifi  ed 
by measuring the length of tubes in random fi  elds. The precapillary cord 
formation assay was performed as described previously (22).JEM VOL. 203, October 30, 2006  2507
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Immunoprecipitation and Western blot analysis. Immunoprecipita-
tion was performed as described previously (23). To analyze the β3 integrin 
tyrosine phosphorylation of WT and DiYF mouse lung microvascular 
endothelial cells, ECs were added to various integrin ligand-coated plates 
and incubated at 37°C for 60 min. Cell lysates containing equal amount of 
proteins were subjected to Western blot analysis using rabbit anti–integrin β3 
[pY747] and [pY759] antibody (Biosource International, Inc). Cell lysates were 
also analyzed for β3 integrin expression as a loading control. Serum-starved 
WT and DiYF ECs were also treated with 20 ng/ml VEGF for 0–60 min. 
Cell lysates were analyzed by Western blot using anti–integrin β3 [pY747], 
anti–integrin β3 [pY759], anti–ERK-1/2 and anti–p-ERK-1/2 (Cell Signal-
ing Technology) antibodies.
Statistical analysis. Values were expressed as mean ± SDs. p values were 
based on the paired t test. Results were considered statically signifi  cant with 
P < 0.05.
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